| abstract |
Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-I gpl20. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-I gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes. |